https://www.amnog.de/en/procedures/benefit-assessment/pitavastatin-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/abirateronacetat-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/pirfenidon-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/boceprevir-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/linagliptin-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/bromfenac-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/ticagrelor-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/azilsartan-medoxomil-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/cabazitaxel-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/galcanezumab-1/ 2026-08-01T16:30:01+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/indacaterol-glycopyrronium-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/afatinib-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/apixaban-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/fingolimod-1/ 2026-07-27T18:30:01+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/regadenoson-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/apixaban-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/collagenase-aus-clostridium-histolyticum-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/eribulin-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/telaprevir-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/retigabin-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/aliskiren-amlodipin-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/tafamidis-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/rilpivirin-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/emtricitabin-rilpivirin-tenofovirdisoproxil-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/fampridin-1/ 2026-08-01T16:30:01+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/extrakt-aus-cannabis-sativa-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/abirateronacetat-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/belatacept-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/belimumab-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/ipilimumab-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/vandetanib-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/vemurafenib-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/pasireotid-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/tegafur-gimeracil-oteracil-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/ivacaftor-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/linagliptin-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/perampanel-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/aclidiniumbromid-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/axitinib-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/ruxolitinib-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/crizotinib-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/colestilan-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/decitabin-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/saxagliptin-metformin-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/brentuximab-vedotin-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/linagliptin-3/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/pixantron-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/aflibercept-1/ 2026-08-01T16:30:01+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/dapagliflozin-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/fidaxomicin-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/ingenolmebutat-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/aflibercept-zaltrap-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/lixisenatid-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/vandetanib-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/pertuzumab-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/saxagliptin-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/saxagliptin-metformin-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/sitagliptin-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/sitagliptin-metformin-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/vildagliptin-metformin-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/vildagliptin-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/bosutinib-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/linaclotid-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/ocriplasmin-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/fluticasonfuroat-vilanterol-trifenatat-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/lisdexamfetamindimesilat-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/nepafenac-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/elvitegravir-cobicistat-emtricitabin-tenofovirdisoproxil-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/ponatinib-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/vismodegib-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/enzalutamid-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/pomalidomid-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/vemurafenib-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/aflibercept-2/ 2026-08-01T16:30:01+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/regorafenib-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/teriflunomid-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/dabrafenib-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/ipilimumab-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/lomitapid-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/emtricitabin-rilpivirin-tenofovirdisoproxil-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/radium-223-dichlorid-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/trastuzumab-emtansin-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/turoctocog-alfa-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/retigabin-3/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/macitentan-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/dolutegravir-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/sofosbuvir-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/dapagliflozin-metformin-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/cobicistat-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/canagliflozin-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/riociguat-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/insulin-degludec-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/dimethylfumarat-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/ruxolitinib-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/cholsaeure-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/perampanel-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/lebende-larven-von-lucilia-sericata-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/mirabegron-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/elosulfase-alfa-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/simeprevir-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/olodaterol-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/insulin-degludec-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/siltuximab-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/fingolimod-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/vedolizumab-1/ 2026-08-01T16:30:01+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/umeclidinium-vilanterol-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/eribulin-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/cabozantinib-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/canagliflozin-metformin-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/empagliflozin-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/obinutuzumab-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/apixaban-3/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/ivacaftor-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/nalmefen-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/propranolol-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/regorafenib-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/daclatasvir-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/teduglutid-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/aflibercept-3/ 2026-08-01T16:30:01+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/idelalisib-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/sipuleucel-t-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/sucroferric-oxyhydroxide-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/dolutegravir-abacavir-lamivudin-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/albiglutid-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/ibrutinib-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/lurasidon-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/simoctocog-alfa-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/alipogentiparvovec-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/ledipasvir-sofosbuvir-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/vildagliptin-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/ataluren-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/tafluprost-timolol-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/enzalutamid-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/nintedanib-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/pasireotid-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/aclidiniumbromid-formoterol-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/dulaglutid-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/dasabuvir-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/ramucirumab-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/ombitasvir-paritaprevir-ritonavir-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/apremilast-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/insulin-degludec-3/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/nintedanib-ofev-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/aflibercept-4/ 2026-08-01T16:30:01+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/eliglustat-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/fingolimod-3/ 2026-08-01T16:30:01+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/ruxolitinib-3/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/insulin-degludec-liraglutid-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/vortioxetin-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/safinamid-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/afatinib-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/ivermectin-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/olaparib-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/secukinumab-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/lomitapid-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/ceritinib-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/lenvatinib-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/belatacept-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/nivolumab-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/edoxaban-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/gaxilose-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/nivolumab-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/netupitant-palonosetron-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/pembrolizumab-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/tiotropium-olodaterol-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/insulin-degludec-liraglutid-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/pertuzumab-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/evolocumab-1/ 2026-08-01T16:30:01+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/asfotase-alfa-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/dabrafenib-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/idebenon-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/panobinostat-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/pomalidomid-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/regorafenib-3/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/sebelipase-alfa-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/trametinib-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/aclidiniumbromid-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/isavuconazol-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/alirocumab-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/fingolimod-4/ 2026-08-01T16:30:01+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/aflibercept-5/ 2026-08-01T16:30:01+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/lumacaftor-ivacaftor-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/ivacaftor-3/ 2026-08-06T11:46:19+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/cobimetinib-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/carfilzomib-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/blinatumomab-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/secukinumab-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/crizotinib-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/elvitegravir-cobicistat-emtricitabin-tenofoviralafenamid-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/efmoroctocog-alfa-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/sacubitril-valsartan-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/rilpivirin-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/mepolizumab-1/ 2026-08-01T16:30:01+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/ibrutinib-3/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/umeclidinium-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/vismodegib-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/brivaracetam-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/afamelanotid-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/ramucirumab-3/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/ramucirumab-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/empagliflozin-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/empagliflozin-metformin-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/idelalisib-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/ticagrelor-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/necitumumab-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/osimertinib-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/nivolumab-4/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/nivolumab-3/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/afatinib-3/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/ramucirumab-4/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/ospemifen-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/emtricitabin-tenofoviralafenamid-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/daratumumab-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/ataluren-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/elotuzumab-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/migalastat-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/albutrepenonacog-alfa-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/eribulin-3/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/talimogen-laherparepvec-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/eftrenonacog-alfa-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/selexipag-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/nivolumab-5/ 2026-08-01T16:30:01+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/obinutuzumab-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/crizotinib-3/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/saxagliptin-3/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/saxagliptin-metformin-3/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/sitagliptin-2/ 2026-08-01T16:30:01+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/sitagliptin-metformin-2/ 2026-08-01T16:30:01+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/ibrutinib-4/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/sofosbuvir-velpatasvir-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/emtricitabin-rilpivirin-tenofoviralafenamid-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/carfilzomib-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/brentuximab-vedotin-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/pitolisant-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/tasimelteon-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/teduglutid-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/trifluridin-tipiracil-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/pembrolizumab-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/ibrutinib-5/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/idelalisib-3/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/lenvatinib-kisplyx-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/crizotinib-4/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/ceritinib-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/opicapon-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/macitentan-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/cabozantinib-cabometyx-1/ 2026-07-28T18:30:01+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/olaratumab-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/palbociclib-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/venetoclax-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/nivolumab-6/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/elbasvir-grazoprevir-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/ixazomib-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/vandetanib-3/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/reslizumab-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/obeticholsaeure-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/lonoctocog-alfa-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/pembrolizumab-3/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/ixekizumab-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/secukinumab-3/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/baricitinib-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/dolutegravir-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/tenofoviralafenamid-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/axitinib-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/osimertinib-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/alectinib-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/tofacitinib-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/trametinib-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/dabrafenib-3/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/pembrolizumab-4/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/rolapitant-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/nivolumab-7/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/etelcalcetid-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/nivolumab-8/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/blinatumomab-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/cerliponase-alfa-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/nusinersen-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/nivolumab-9/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/inotuzumab-ozogamicin-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/ceritinib-3/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/glecaprevir-pibrentasvir-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/saxagliptin-metformin-4/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/ledipasvir-sofosbuvir-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/daratumumab-3/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/sofosbuvir-velpatasvir-voxilaprevir-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/sarilumab-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/brodalumab-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/darunavir-cobicistat-emtricitabin-tenofoviralafenamid-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/dimethylfumarat-skilarence-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/avelumab-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/atezolizumab-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/atezolizumab-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/elosulfase-alfa-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/pembrolizumab-5/ 2026-08-06T11:46:19+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/ribociclib-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/sofosbuvir-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/obinutuzumab-3/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/midostaurin-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/telotristatethyl-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/cabozantinib-cabometyx-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/nonacog-beta-pegol-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/tivozanib-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/elvitegravir-cobicistat-emtricitabin-tenofovirdisoproxil-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/cenegermin-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/perampanel-3/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/guselkumab-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/dupilumab-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/cladribin-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/niraparib-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/abirateronacetat-3/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/dapagliflozin-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/dapagliflozin-metformin-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/alectinib-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/allogene-genetisch-modifizierte-t-zellen-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/elvitegravir-cobicistat-emtricitabin-tenofoviralafenamid-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/brentuximab-vedotin-3/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/lumacaftor-ivacaftor-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/ocrelizumab-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/ipilimumab-3/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/fluticasonfuroat-vilanterol-trifenatat-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/letermovir-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/benralizumab-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/sonidegib-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/insulin-glargin-lixisenatid-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/ixekizumab-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/glycerolphenylbutyrat-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/fluticasonfuroat-umeclidinium-vilanterol-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/evolocumab-2/ 2026-08-01T16:30:01+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/glycopyrroniumbromid-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/patiromer-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/emicizumab-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/bezlotoxumab-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/burosumab-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/cariprazin-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/ertugliflozin-sitagliptin-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/hydrocortison-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/rurioctocog-alfa-pegol-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/tofacitinib-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/extrakt-aus-cannabis-sativa-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/carfilzomib-3/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/darvadstrocel-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/bosutinib-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/dolutegravir-rilpivirin-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/cabozantinib-cabometyx-3/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/olaparib-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/velmanase-alfa-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/bictegravir-emtricitabin-tenofoviralafenamid-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/pertuzumab-3/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/nivolumab-10/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/ipilimumab-4/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/osimertinib-3/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/brivaracetam-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/ingenolmebutat-2/ 2026-08-06T11:46:19+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/bosutinib-3/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/gemtuzumab-ozogamicin-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/nivolumab-11/ 2026-07-28T18:30:01+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/tofacitinib-4/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/tofacitinib-3/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/tisagenlecleucel-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/tisagenlecleucel-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/daratumumab-4/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/vestronidase-alfa-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/caplacizumab-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/tenofoviralafenamid-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/sitagliptin-3/ 2026-08-01T16:30:01+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/mepolizumab-2/ 2026-08-01T16:30:01+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/daunorubicin-cytarabin-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/lenvatinib-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/palbociclib-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/encorafenib-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/binimetinib-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/metreleptin-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/inotersen-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/patisiran-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/dabrafenib-4/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/trametinib-3/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/durvalumab-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/ocriplasmin-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/pembrolizumab-6/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/erenumab-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/semaglutid-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/abemaciclib-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/abemaciclib-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/axicabtagen-ciloleucel-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/axicabtagen-ciloleucel-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/alirocumab-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/tildrakizumab-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/fluticasonfuroat-umeclidinium-vilanterol-trelegy-ellipta-elebrato-ellipta-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/insulin-degludec-4/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/venetoclax-3/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/venetoclax-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/enzalutamid-3/ 2026-07-28T18:30:01+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/tezacaftor-ivacaftor-1/ 2026-07-28T18:30:01+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/cabozantinib-cabometyx-4/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/atezolizumab-3/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/fingolimod-5/ 2026-08-01T16:30:01+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/pembrolizumab-7/ 2026-08-06T11:46:19+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/damoctocog-alfa-pegol-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/ribociclib-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/melatonin-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/bedaquilin-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/brigatinib-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/glycerolphenylbutyrat-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/doravirin-lamivudin-tenofovirdisoproxil-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/doravirin-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/lanadelumab-1/ 2026-07-28T18:30:01+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/apalutamid-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/mexiletin-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/nivolumab-12/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/ipilimumab-5/ 2026-07-27T18:30:01+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/lenvatinib-3/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/blinatumomab-3/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/lumacaftor-ivacaftor-3/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/blinatumomab-4/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/pembrolizumab-8/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/emicizumab-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/rucaparib-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/brentuximab-vedotin-4/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/rucaparib-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/regadenoson-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/nintedanib-ofev-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/glecaprevir-pibrentasvir-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/pembrolizumab-9/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/pembrolizumab-10/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/voretigen-neparvovec-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/radium-223-dichlorid-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/fremanezumab-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/dapagliflozin-3/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/lisdexamfetamindimesilat-elvanse-adult-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/dacomitinib-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/pomalidomid-3/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/lorlatinib-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/risankizumab-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/empagliflozin-linagliptin-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/olaparib-4/ 2026-07-28T18:30:01+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/dapagliflozin-4/ 2026-08-01T16:30:01+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/dapagliflozin-metformin-3/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/pegvaliase-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/vigabatrin-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/vigabatrin-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/olaparib-3/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/cemiplimab-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/ravulizumab-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/dolutegravir-lamivudin-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/turoctocog-alfa-pegol-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/volanesorsen-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/ropeginterferon-alfa-2b-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/ibrutinib-7/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/ibrutinib-6/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/andexanet-alfa-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/dupilumab-3/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/dupilumab-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/ramucirumab-5/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/ivacaftor-5/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/ivacaftor-6/ 2026-07-28T18:30:01+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/ivacaftor-7/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/ivacaftor-8/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/ivacaftor-9/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/ivacaftor-10/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/ivacaftor-11/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/burosumab-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/elotuzumab-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/atezolizumab-7/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/atezolizumab-6/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/atezolizumab-4/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/asfotase-alfa-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/trifluridin-tipiracil-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/atezolizumab-5/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/larotrectinib-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/cannabidiol-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/niraparib-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/cannabidiol-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/betibeglogene-autotemcel-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/belimumab-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/pembrolizumab-12/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/pembrolizumab-11/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/pembrolizumab-13/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/dupilumab-4/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/avelumab-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/gilteritinib-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/neratinib-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/ivacaftor-12/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/trastuzumab-emtansin-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/upadacitinib-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/dulaglutid-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/ramucirumab-6/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/daratumumab-6/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/daratumumab-5/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/bedaquilin-3/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/siponimod-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/polatuzumab-vedotin-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/ribociclib-3/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/ribociclib-4/ 2026-07-28T18:30:01+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/apalutamid-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/tafamidis-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/abemaciclib-3/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/riociguat-3/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/riociguat-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/tisagenlecleucel-4/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/tisagenlecleucel-3/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/romosozumab-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/fidaxomicin-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/brolucizumab-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/cobicistat-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/apalutamid-3/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/trifluridin-tipiracil-3/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/avelumab-3/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/givosiran-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/insulin-glargin-lixisenatid-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/venetoclax-4/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/darolutamid-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/brigatinib-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/solriamfetol-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/enzalutamid-4/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/apremilast-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/naldemedin-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/ponatinib-3/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/ponatinib-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/talazoparib-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/mogamulizumab-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/brentuximab-vedotin-5/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/tezacaftor-ivacaftor-3/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/tezacaftor-ivacaftor-2/ 2026-07-28T18:30:01+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/ivacaftor-13/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/fostamatinib-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/encorafenib-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/caplacizumab-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/ozanimod-1/ 2026-08-01T16:30:01+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/osilodrostat-1/ 2026-07-28T18:30:01+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/ixekizumab-3/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/ixekizumab-4/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/ledipasvir-sofosbuvir-3/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/luspatercept-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/luspatercept-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/sofosbuvir-3/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/ravulizumab-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/indacaterol-mometason-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/glasdegib-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/nintedanib-ofev-4/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/indacaterolacetat-glycopyrroniumbromid-mometasonfuroat-1/ 2026-08-01T16:30:01+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/trifaroten-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/nintedanib-ofev-3/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/secukinumab-4/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/secukinumab-6/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/secukinumab-5/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/ibalizumab-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/entrectinib-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/entrectinib-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/ivacaftor-15/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/ivacaftor-14/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/ivacaftor-tezacaftor-elexacaftor-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/ivacaftor-tezacaftor-elexacaftor-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/bulevirtid-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/alpelisib-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/belantamab-mafodotin-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/sofosbuvir-velpatasvir-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/durvalumab-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/ibrutinib-8/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/filgotinib-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/cannabidiol-3/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/cannabidiol-4/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/semaglutid-rybelsus-ozempic-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/bempedoinsaeure-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/bempedoinsaeure-ezetimib-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/burosumab-3/ 2026-07-28T18:30:01+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/avapritinib-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/baricitinib-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/atezolizumab-8/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/amikacin-liposomal-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/acalabrutinib-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/acalabrutinib-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/acalabrutinib-3/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/crizanlizumab-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/dapagliflozin-5/ 2026-08-01T16:30:01+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/ivacaftor-16/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/ivacaftor-17/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/ivacaftor-18/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/ivacaftor-19/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/niraparib-3/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/tafamidis-3/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/tafamidis-4/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/tezacaftor-ivacaftor-4/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/sebelipase-alfa-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/nusinersen-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/guselkumab-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/olaparib-7/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/olaparib-6/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/olaparib-5/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/bedaquilin-1/ 2026-07-27T18:30:01+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/ceftarolinfosamil-1/ 2026-07-27T18:30:01+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/chloroprocain-1/ 2026-07-27T18:30:01+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/defibrotid-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/dexmedetomidin-1/ 2026-07-27T18:30:01+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/dinutuximab-beta-1/ 2026-07-27T18:30:01+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/indigocarmin-1/ 2026-07-27T18:30:01+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/landiololhydrochlorid-1/ 2026-07-27T18:30:01+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/lutetium-177lu-oxodotreotid-1/ 2026-07-27T18:30:01+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/piperaquintetraphosphat-dihydroartemisinin-1/ 2026-07-27T18:30:01+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/cefiderocol-1/ 2026-07-27T18:30:01+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/ceftolozan-tazobactam-4/ 2026-07-27T18:30:01+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/ceftolozan-tazobactam-3/ 2026-07-27T18:30:01+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/ceftolozan-tazobactam-2/ 2026-07-27T18:30:01+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/ceftolozan-tazobactam-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/dabigatranetexilat-1/ 2026-07-27T18:30:01+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/daratumumab-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/denosumab-1/ 2026-07-27T18:30:01+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/ibrutinib-2/ 2026-07-27T18:30:01+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/ivacaftor-4/ 2026-07-27T18:30:01+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/parathyroidhormon-1/ 2026-07-27T18:30:01+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/prasteron-1/ 2026-07-27T18:30:01+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/retigabin-2/ 2026-07-27T18:30:01+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/rivaroxaban-1/ 2026-07-27T18:30:01+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/saxagliptin-2/ 2026-07-27T18:30:01+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/sucroferric-oxyhydroxide-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/perampanel-5/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/perampanel-4/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/nivolumab-13/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/ipilimumab-6/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/lumasiran-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/lenvatinib-kisplyx-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/dupilumab-5/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/afamelanotid-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/nivolumab-14/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/carfilzomib-4/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/upadacitinib-3/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/upadacitinib-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/inclisiran-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/fenfluramin-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/niraparib-4/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/dolutegravir-3/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/levofloxacin-dexamethason-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/pertuzumab-trastuzumab-3/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/pertuzumab-trastuzumab-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/pertuzumab-trastuzumab-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/blinatumomab-5/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/brexucabtagen-autoleucel-autologe-anti-cd19-transduzierte-cd3-zellen-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/eszopiclon-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/baloxavir-marboxil-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/baloxavir-marboxil-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/beclometason-formoterol-glycopyrronium-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/esketamin-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/esketamin-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/avelumab-4/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/tezacaftor-ivacaftor-5/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/onasemnogen-abeparvovec-1/ 2026-07-27T18:30:01+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/selpercatinib-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/selpercatinib-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/selpercatinib-3/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/tucatinib-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/fedratinib-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/imlifidase-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/bedaquilin-4/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/pembrolizumab-15/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/pembrolizumab-16/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/pembrolizumab-14/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/fostemsavir-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/avatrombopag-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/avatrombopag-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/remdesivir-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/natrium-zirkonium-cyclosilikat-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/nivolumab-15/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/pemigatinib-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/atidarsagen-autotemcel-otl-200-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/rilpivirin-rekambys-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/nivolumab-16/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/cabozantinib-cabometyx-5/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/risdiplam-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/erenumab-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/cabotegravir-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/cannabidiol-5/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/belimumab-3/ 2026-07-27T18:30:01+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/obinutuzumab-5/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/obinutuzumab-4/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/obinutuzumab-6/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/onasemnogen-abeparvovec-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/lanadelumab-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/isatuximab-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/isatuximab-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/atezolizumab-9/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/cenobamat-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/enzalutamid-5/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/bosutinib-4/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/ivacaftor-20/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/ivacaftor-21/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/ivacaftor-22/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/ivacaftor-tezacaftor-elexacaftor-3/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/ivacaftor-tezacaftor-elexacaftor-4/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/ivacaftor-tezacaftor-elexacaftor-5/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/ponesimod-1/ 2026-08-01T16:30:01+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/berotralstat-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/venetoclax-5/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/tagraxofusp-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/dostarlimab-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/elotuzumab-3/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/osimertinib-4/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/nivolumab-17/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/glecaprevir-pibrentasvir-3/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/cabozantinib-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/brentuximab-vedotin-6/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/angiotensin-ii-acetat-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/tralokinumab-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/empagliflozin-3/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/satralizumab-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/daratumumab-8/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/daratumumab-7/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/cemiplimab-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/cemiplimab-3/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/nivolumab-18/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/blinatumomab-6/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/teriflunomid-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/selumetinib-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/upadacitinib-4/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/dapagliflozin-6/ 2026-08-01T16:30:01+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/relugolix-estradiol-norethisteronacetat-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/tirbanibulin-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/tofacitinib-5/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/icosapent-ethyl-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/migalastat-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/nivolumab-19/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/misoprostol-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/tafasitamab-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/odevixibat-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/vericiguat-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/bimekizumab-1/ 2026-08-01T16:30:01+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/roxadustat-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/tofacitinib-6/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/ravulizumab-3/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/lumacaftor-ivacaftor-4/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/daratumumab-9/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/vosoritid-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/vandetanib-4/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/solriamfetol-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/erdnussprotein-als-entfettetes-pulver-von-arachis-hypogaea-l-semen-erdnuesse-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/albutrepenonacog-alfa-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/sofosbuvir-velpatasvir-voxilaprevir-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/pitolisant-ozawade-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/ixazomib-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/pembrolizumab-18/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/pembrolizumab-17/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/elbasvir-grazoprevir-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/delamanid-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/cefiderocol-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/lusutrombopag-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/sacituzumab-govitecan-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/risankizumab-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/nivolumab-20/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/ertugliflozin-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/mepolizumab-5/ 2026-08-01T16:30:01+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/mepolizumab-3/ 2026-08-01T16:30:01+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/mepolizumab-4/ 2026-08-01T16:30:01+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/filgotinib-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/abemaciclib-4/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/ponesimod-2/ 2026-08-01T16:30:01+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/pembrolizumab-20/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/pembrolizumab-19/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/lenvatinib-4/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/lenvatinib-kisplyx-3/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/dapagliflozin-7/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/ozanimod-2/ 2026-08-01T16:30:01+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/tofacitinib-7/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/pralsetinib-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/ripretinib-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/diroximelfumarat-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/evolocumab-3/ 2026-08-01T16:30:01+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/idecabtagen-vicleucel-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/ceftolozan-tazobactam-5/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/remdesivir-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/amivantamab-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/abrocitinib-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/imipenem-cilastatin-relebactam-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/duvelisib-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/duvelisib-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/burosumab-4/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/burosumab-5/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/isofluran-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/calcifediol-1/ 2026-08-01T16:30:01+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/sofosbuvir-velpatasvir-3/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/sotorasib-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/avacopan-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/ivacaftor-23/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/ivacaftor-24/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/ivacaftor-25/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/ivacaftor-26/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/ivacaftor-27/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/ivacaftor-tezacaftor-elexacaftor-6/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/ivacaftor-tezacaftor-elexacaftor-7/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/ivacaftor-tezacaftor-elexacaftor-8/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/ivacaftor-tezacaftor-elexacaftor-9/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/ivacaftor-tezacaftor-elexacaftor-10/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/vedolizumab-2/ 2026-08-01T16:30:01+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/tepotinib-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/lorlatinib-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/brivaracetam-3/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/daratumumab-10/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/empagliflozin-4/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/idebenon-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/pegcetacoplan-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/voretigen-neparvovec-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/dolutegravir-4/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/somatrogon-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/anifrolumab-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/avapritinib-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/glucarpidase-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/dupilumab-6/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/casirivimab-imdevimab-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/casirivimab-imdevimab-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/nivolumab-23/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/nivolumab-22/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/nivolumab-21/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/doravirin-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/doravirin-lamivudin-tenofovirdisoproxil-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/ceftazidim-avibactam-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/ceftolozan-tazobactam-6/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/imipenem-cilastatin-relebactam-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/abemaciclib-5/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/brolucizumab-2/ 2026-08-01T16:30:01+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/tebentafusp-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/sotrovimab-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/voxelotor-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/axicabtagen-ciloleucel-3/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/tisagenlecleucel-5/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/polatuzumab-vedotin-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/cabozantinib-cabometyx-6/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/setmelanotid-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/enfortumab-vedotin-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/zanubrutinib-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/dimethylfumarat-2/ 2026-08-06T11:38:43+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/cerliponase-alfa-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/nirmatrelvir-ritonavir-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/palbociclib-3/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/selpercatinib-4/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/pembrolizumab-21/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/mosunetuzumab-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/macimorelinacetate-1/ 2026-07-27T18:30:01+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/atezolizumab-10/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/secukinumab-7/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/secukinumab-8/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/eravacyclin-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/inebilizumab-1/ 2026-08-01T16:30:01+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/glycopyrronium-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/pembrolizumab-30/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/pembrolizumab-29/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/pembrolizumab-28/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/pembrolizumab-27/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/pembrolizumab-26/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/pembrolizumab-25/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/pembrolizumab-24/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/pembrolizumab-23/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/pembrolizumab-22/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/trastuzumab-deruxtecan-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/trastuzumab-deruxtecan-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/eladocagene-exuparvovec-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/capmatinib-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/ceftolozan-tazobactam-7/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/birkenrindenextrakt-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/upadacitinib-6/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/upadacitinib-5/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/olaparib-8/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/eptinezumab-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/efgartigimod-alfa-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/burosumab-6/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/lisocabtagen-maraleucel-1/ 2026-08-01T16:30:01+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/valoctocogen-roxaparvovec-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/brexucabtagen-autoleucel-autologe-anti-cd19-transduzierte-cd3-zellen-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/selpercatinib-5/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/pertuzumab-trastuzumab-4/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/pertuzumab-4/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/olipudase-alfa-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/melphalanflufenamid-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/asciminib-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/selinexor-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/selinexor-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/difelikefalin-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/faricimab-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/lonafarnib-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/relugolix-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/vutrisiran-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/remdesivir-3/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/remdesivir-4/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/faricimab-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/tixagevimab-cilgavimab-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/ravulizumab-4/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/olaparib-9/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/elvitegravir-cobicistat-emtricitabin-tenofoviralafenamid-3/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/daridorexant-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/tralokinumab-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/tezepelumab-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/maribavir-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/olopatadin-mometason-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/zanubrutinib-4/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/zanubrutinib-3/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/zanubrutinib-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/latanoprost-netarsudil-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/abemaciclib-6/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/sutimlimab-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/bictegravir-emtricitabin-tenofoviralafenamid-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/risankizumab-3/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/olaparib-10/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/maralixibat-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/lutetium-177lu-vipivotidtetraxetan-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/spesolimab-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/ibrutinib-9/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/sotorasib-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/trastuzumab-deruxtecan-4/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/trastuzumab-deruxtecan-3/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/ciltacabtagen-autoleucel-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/fenfluramin-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/dapagliflozin-8/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/dolutegravir-abacavir-lamivudin-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/finerenon-1/ 2026-08-01T16:30:01+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/finerenon-2/ 2026-08-01T16:30:01+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/emicizumab-3/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/voclosporin-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/esketamin-3/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/dupilumab-9/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/dupilumab-8/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/dupilumab-7/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/tremelimumab-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/tremelimumab-tremelimumab-astrazeneca-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/durvalumab-5/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/durvalumab-4/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/rucaparib-3/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/durvalumab-3/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/luspatercept-3/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/dulaglutid-3/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/pitolisant-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/olaparib-11/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/darolutamid-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/belantamab-mafodotin-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/deucravacitinib-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/tabelecleucel-1/ 2026-08-01T16:30:01+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/lasmiditan-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/dalbavancin-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/upadacitinib-7/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/etranacogen-dezaparvovec-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/cemiplimab-4/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/cemiplimab-5/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/tixagevimab-cilgavimab-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/luspatercept-5/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/luspatercept-4/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/loncastuximab-tesirin-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/setmelanotid-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/lisocabtagen-maraleucel-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/ravulizumab-5/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/secukinumab-9/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/sacubitril-valsartan-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/selumetinib-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/bimekizumab-4/ 2026-08-01T16:30:01+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/bimekizumab-3/ 2026-08-01T16:30:01+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/bimekizumab-2/ 2026-08-01T16:30:01+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/riociguat-4/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/axicabtagen-ciloleucel-5/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/axicabtagen-ciloleucel-6/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/axicabtagen-ciloleucel-4/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/nivolumab-25/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/nivolumab-24/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/mirikizumab-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/ivosidenib-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/ivosidenib-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/cipaglucosidase-alfa-1/ 2026-08-01T16:30:01+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/dalbavancin-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/empagliflozin-5/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/eftrenonacog-alfa-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/mavacamten-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/glofitamab-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/nivolumab-26/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/bedaquilin-5/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/lumacaftor-ivacaftor-5/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/trifluridin-tipiracil-4/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/migalastat-3/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/sacituzumab-govitecan-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/nonacog-beta-pegol-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/tisagenlecleucel-7/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/tisagenlecleucel-6/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/vosoritid-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/teclistamab-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/lonapegsomatropin-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/risdiplam-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/nivolumab-27/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/pegunigalsidase-alfa-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/talquetamab-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/epcoritamab-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/sirolimus-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/brolucizumab-3/ 2026-08-01T16:30:01+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/somapacitan-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/elacestrant-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/baricitinib-4/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/baricitinib-5/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/baricitinib-6/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/baricitinib-3/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/midostaurin-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/midostaurin-3/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/brentuximab-vedotin-7/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/niraparib-abirateronacetat-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/tirzepatid-1/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/trastuzumab-deruxtecan-5/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/vosoritid-3/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/relugolix-estradiol-norethisteronacetat-2/ 2026-08-06T18:46:26+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/daratumumab-11/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/patisiran-2/ 2026-07-27T22:11:48+02:00 0.5 https://www.amnog.de/en/procedures/benefit-assessment/tebentafusp-2/ 2026-07-27T22:11:48+02:00 0.5